Agree, the high end of upside is;
200 doctors * 20 calls a day * 50% respiratory case * 30%- 75% use Resapp (This could be wrong) * $5 a use = ~1250 uses a day = $6,250 a day or ~$2.2m annualized. I get these are high level and could move +/- reasonable % either way.
$2.2m is not even half a year of runway for company.
Still if we get anything near that upside it would trigger a massive rerate of shares.
I expect a CR once the Share price rises on any further positive news.
- Forums
- ASX - By Stock
- RAP
- Ann: Medgate commences European ResAppDx trial
Ann: Medgate commences European ResAppDx trial, page-19
-
- There are more pages in this discussion • 149 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online